Is it necessary and feasible to increase the efficiency of 2-µm thulium laser resection of the prostate?

Zhuo, Jian; Xia, Shujie

doi:10.1038/aja.2013.28

Cited by 7 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If the surgeon is already familiar with TURP, he can begin performing the procedure on his next patient, under close supervision, after watching a single case. Thus, the learning curve for TmLRP requires the mastery of at least three cases [26]. Considering a bareended reusable laser fiber was used in TmLRP, treatment cost can be lowered.…”

Section: Discussionmentioning

confidence: 99%

Long-term results of thulium laser resection of the prostate: a prospective study at multiple centers

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term results of thulium laser resection of the prostate: a prospective study at multiple centers

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…Thulium laser resection of the prostate (TmLRP) is one of the major minimally invasive surgical methods for the treatment of benign prostatic hyperplasia (BPH) (Parsons et al, 2020; Xia et al, 2008; Zhuo & Xia, 2013). It has been shown to be efficient and safe with faster hemostasis, higher precision, and lower perioperative morbidity (H. Wei, Shao, et al, 2014; H. Wei, Zhuo, et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

ROS–NLRP3 signaling pathway induces sterile inflammation after thulium laser resection of the prostate

Wang

Zhao

et al. 2022

Journal Cellular Physiology

Self Cite

View full text Add to dashboard Cite

The sterile inflammation (SI) of the urinary tract is a common problem requiring serious consideration after prostatectomy. This study mainly focuses on the role of the reactive oxygen species–NLR family, pyrin domain‐containing 3 (ROS–NLRP3) signaling pathway in SI after thulium laser resection of the prostate (TmLRP). Urinary cytokines were determined in patients who received TmLRP, and heat shock protein 70 (HSP70) was detected in the resected tissues. The involvement of ROS signaling in HSP70‐induced inflammation was explored in THP‐1 cells with or without N‐acetyl‐ l‐cysteine (NAC) pretreatment. The function of NLRP3 and Caspase‐1 was determined by Western blot analysis, enzyme‐linked immunosorbent assay (ELISA), and polymerase chain reaction. These phenomena and mechanisms were verified by the beagle models that received TmLRP. Clinical urine samples after TmLRP showed high expression of inflammatory factors and peaked 3–5 days after surgery. The high expression of HSP70 in the resected tissues was observed. After HSP70 stimulation, the expression of ROS, NLRP3, Caspase‐1, and interleukin‐18 (IL‐18) increased significantly and could be reduced by ROS inhibitor NAC. The expression of IL‐1β and IL‐18 could be inhibited by NLRP3 or Caspase‐1 inhibitors. In beagle models that received TmLRP, HSP70, NLRP3, Caspase‐1, IL‐1β, and IL‐18 were highly expressed in the wound tissue or urine, and could also be reduced by NAC pretreatment. Activation of the ROS–NLRP3 signaling pathway induces SI in the wound after prostatectomy. Inhibition of this pathway may be effective for clinical prevention and treatment of SI and related complications after prostatectomy.

show abstract

“…From the technological point of view, the surgical alternative use of laser energy might reduce the risks of this difficult surgical procedure and is likely to compete with TURP and classical open adenomectomy [8][9][10] . The use of Thulium:YAG laser in retrograde transurethral enucleation of the prostate seems to become a new step in the surgical treatment of BPH, thus being probably the new gold standard therapy [11][12][13] . The implementation of Thulium:YAG vapoenucleation laser of the prostate (Thu-VEP) will allow patients with large BPH, who have traditionally undergone an open adenomectomy or monopolar transurethral resection of the prostate, to follow a minimally invasive endoscopic treatment [14][15][16] .…”

Section: Introductionmentioning

confidence: 99%

Thulium: Yag laser vapoenucleation of the prostate vs. standard transurethral resection in benign prostatic hyperplasia treatment

Plesacov

Ghicavii

2021

Arch Balk Med Union

View full text Add to dashboard Cite

Vapoénucléation prostatique à Thulium: YAG laser vs résection transurétrale monopolaire dans le traitement de l'hyperplasie bénigne de la prostate Introduction. L'utilisation du laser Thulium:YAG dans l'énucléation transurétrale rétrograde de la prostate peut devenir une étape avancée dans la chirurgie HPB. La mise en place de la vapoénucléation de la prostate par le laser Thulium:YAG permettra aux patients souffrant de HBP volumineuse, traités traditionnellement par l'adénomectomie classique ouverte ou la résection transurétrale monopolaire de la prostate, de suivre le traitement endoscopique minimal invasif par l'utilisation de l'énergie du laser. L'objectif de l'étude a été l'évaluation comparative de la vapoénucléation de la prostate au laser Thulium:YAG et la résection transurétrale standard dans le traitement de l'hyperplasie bénigne de la prostate.

show abstract

Is it necessary and feasible to increase the efficiency of 2-µm thulium laser resection of the prostate?

Cited by 7 publications

References 13 publications

Long-term results of thulium laser resection of the prostate: a prospective study at multiple centers

Long-term results of thulium laser resection of the prostate: a prospective study at multiple centers

ROS–NLRP3 signaling pathway induces sterile inflammation after thulium laser resection of the prostate

Thulium: Yag laser vapoenucleation of the prostate vs. standard transurethral resection in benign prostatic hyperplasia treatment

Contact Info

Product

Resources

About